OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Income Before Tax

Last Annual Value

-8.88M

3-Year CAGR

-6%

5-Year CAGR

-330%

10-Year CAGR

-107%

OT

OS Therapies Incorporated Competitors Analysis of Income Before Tax

OSTX · NYSE
CompanyIncome Before Tax
CAGR 3Y
CAGR 5Y
CAGR 10Y
-8.88M
N/AN/AN/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
-16.29M
N/AN/AN/A
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
-11.99M
N/AN/AN/A
-23.88M
N/AN/AN/A
-26.10M
N/AN/AN/A
-10.41M
N/AN/AN/A
-60.82M
N/AN/AN/A
-38.97M
N/AN/AN/A
-12.28M
N/AN/AN/A
-28.62M
N/AN/AN/A
-63976.69B
N/AN/AN/A
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42